Funded By www.bloodcancer.org.uk
2021-2024 Egyptian Ministry of Higher Education PhD scholarships x 3.
2021-2023 NHS Greater Glasgow and Clyde Endowment Fellowship Funding Award. The role of the Bone Marrow Microenvironment in Acute Myeloid Leukaemia (AML) Drug Resistance. Karen Keeshan and Alison Laing
2020-2021 Cyclacel Ltd. Comparative study of CYC065 with MCL1 and CDK9 inhibitors. Principal investigator: Prof Mhairi Copland and Dr Karen Keeshan
2020-2023 The Kay Kendell Leukaemia Fund. Analysis of the potential of mannose as a new therapy for AML. Prof Kevin Ryan. Co-Investigator: Dr Karen Keeshan
2021-2021 Medical Research Council Confidence in Concept award. Developing TRIB2 as a predictive biomarker for acute myeloid leukaemia sensitivity to the clinical covalent multi-ERBB compounds.
2019-2023 Blood Cancer UK. Targeting ERBB signalling in acute myeloid leukaemia.
2019-2022 Saudi Arabia Government PhD scholarship.
2016-2020 Yorkhill Leukaemia & Cancer Research Fund. Investigation of CD33-targeted therapy in childhood acute myeloid leukaemia (AML).
2012-2018 Children with Cancer (CWC). Non clinical Senior Lecturer in paediatric haematology.
2012-2018 The Howat foundation Ltd. Non clinical Senior Lecturer in paediatric haematology
Dr Karen Keeshan is an expert panel evaluator for;
Horizon 2020 Marie Sklodowska-Curie Actions
Italian Cariplo Foundation
Spanish “la Caixa” Foundation
The Beatriu de Pinós programme
Ad hoc Expert Evaluator UK and EU government agencies and charities e.g. MRC, BBSRC, CSO, CR-UK, CCLG, KKLF, NWCR, EHA